Abbott Reports 11 Percent Ongoing Earnings-Per-Share Growth in Second Quarter; Raises 2011 EPS Guidance Range
By Abbott, PRNETuesday, July 19, 2011
ABBOTT PARK, Illinois, July 20, 2011 -
– Reports 9 Percent Sales Growth
with 23 Percent Growth in Emerging Markets –
Abbott (NYSE: ABT) today announced financial results for the
second quarter ended June 30, 2011.
- Diluted earnings per share, excluding specified items, were
$1.12, at the high end of Abbott’s previous guidance range and
reflecting 10.9 percent growth. Diluted earnings per share under
Generally Accepted Accounting Principles (GAAP) were $1.23,
reflecting growth of 48.2 percent, including specified items.
- Worldwide sales increased 9 percent to $9.6 billion, including
a favorable 4.6 percent effect of foreign exchange. Sales were led
by a 13 percent increase in Proprietary Pharmaceuticals sales.
Durable Growth Business sales increased 7.5 percent, driven by
double-digit growth in International Nutritionals, Point of Care
Diagnostics and Established Pharmaceuticals. Innovation-Driven
Device Business sales increased 3.1 percent, including double-digit
growth in Molecular Diagnostics. - Emerging markets sales were nearly $2.6 billion, up 23.2
percent from the prior year, with strong growth across all of
Abbott’s operating divisions. - The gross margin ratio was 60.2 percent in the second quarter,
driven by favorable product mix. - Abbott is raising its previous ongoing earnings-per-share
guidance range for the full-year 2011 to $4.58 to $4.68, confirming
its outlook for double-digit growth over 2010 at the midpoint of
the range. The previously issued guidance range was $4.54 to
$4.64.
“Abbott is well-positioned for a strong second half of the year
as we remain on track for double-digit EPS growth in 2011,” said
Miles D. White, chairman and chief executive officer, Abbott.
“We’re also pleased with our growth in emerging markets, as well as
the progress of our broad-based pipeline, including several new
product approvals, regulatory submissions and clinical trial
initiations.”
The following is a summary of second-quarter 2011 sales by major
business category.
Sales ($ in millions)
U.S. Int'l Total
Total Sales 3,938 5,678 9,616
Durable Growth:
Nutritionals 655 835 1,490
Established Pharmaceuticals(a) -- 1,339 1,339
Core Laboratory Diagnostics 152 704 856
Diabetes Care 133 201 334
Point of Care Diagnostics 60 18 78
Subtotal 1,000 3,097 4,097
Proprietary Pharmaceuticals 2,302 1,860 4,162
Innovation-Driven Devices:
Vascular 395 440 835
Medical Optics 102 187 289
Molecular Diagnostics 45 60 105
Subtotal 542 687 1,229
Other Sales(b) 94 34 128
% Change vs. 2Q10
Int'l Total
U.S. Operational Reported Operational Reported
Total Sales 3.9 4.7 12.8 4.4 9.0
Durable Growth:
Nutritionals (3.6) 8.2 13.7 2.6 5.4
Established
Pharmaceuticals(a) n/a 3.2 10.3 3.2 10.3
Core Laboratory
Diagnostics 4.4 0.7 8.7 1.4 7.9
Diabetes Care 4.3 (6.7) 1.7 (2.4) 2.7
Point of Care
Diagnostics 17.6 10.5 16.3 16.0 17.3
Subtotal (0.4) 3.3 10.3 2.4 7.5
Proprietary
Pharmaceuticals 8.8 9.1 18.8 8.9 13.0
Innovation-Driven
Devices:
Vascular (9.5) 1.1 10.4 (4.4) ---
Medical Optics 2.9 (0.2) 10.3 0.9 7.5
Molecular
Diagnostics 5.5 20.7 30.5 13.4 18.5
Subtotal (6.2) 2.2 11.9 (1.9) 3.1
Other Sales(b) (1.5) (28.1) (25.8) (8.5) (7.7)
Notes: 1) See "Consolidated Statement of Earnings" for more
information.
2) "Operational" growth reflects percentage change over the
prior year excluding the impact of exchange rates.
(a) Established Pharmaceuticals includes sales of branded generics
outside of the United States.
(b) Includes sales primarily from Contract Pharmaceutical Manufacturing
and Animal Health.
n/a = Not applicable
The following is a summary of first-half 2011 sales by major
business category.
Sales ($ in millions)
U.S. Int'l Total
Total Sales 7,455 11,202 18,657
Durable Growth:
Nutritionals 1,293 1,621 2,914
Established Pharmaceuticals(a) -- 2,634 2,634
Core Laboratory Diagnostics 305 1,363 1,668
Diabetes Care 262 398 660
Point of Care Diagnostics 115 33 148
Subtotal 1,975 6,049 8,024
Proprietary Pharmaceuticals 4,229 3,716 7,945
Innovation-Driven Devices:
Vascular 784 895 1,679
Medical Optics 201 356 557
Molecular Diagnostics 91 114 205
Subtotal 1,076 1,365 2,441
Other Sales(b) 175 72 247
% Change vs. 1H10
Int'l Total
U.S. Operational Reported Operational Reported
Total Sales 5.8 12.9 18.2 9.8 12.9
Durable Growth:
Nutritionals (2.2) 10.0 14.7 4.1 6.5
Established
Pharmaceuticals(a) n/a 30.8 36.4 30.8 36.4
Core Laboratory
Diagnostics 4.5 3.0 7.9 3.3 7.3
Diabetes Care 4.8 2.2 7.4 3.2 6.3
Point of Care
Diagnostics 12.1 11.4 15.6 12.0 12.9
Subtotal 0.4 15.8 20.9 11.4 15.1
Proprietary
Pharmaceuticals 10.5 9.5 14.7 10.0 12.4
Innovation-Driven
Devices:
Vascular (7.8) 15.8 22.5 3.1 6.2
Medical Optics 0.4 0.6 8.0 0.5 5.1
Molecular
Diagnostics 3.7 22.6 28.1 13.2 16.0
Subtotal (5.5) 11.9 18.7 3.3 6.7
Other Sales(b) 54.5 15.4 16.5 23.6 24.1
Notes: 1) See "Consolidated Statement of Earnings" for more
information.
2) "Operational" growth reflects percentage change over the
prior year excluding the impact of exchange rates.
(a) Established Pharmaceuticals includes sales of branded generics
outside of the United States.
(b) Includes sales primarily from Contract Pharmaceutical Manufacturing
and Animal Health.
n/a = Not applicable
The following is a summary of second-quarter 2011 sales for
select products.
Sales ($ in millions)
U.S. Int'l Total
HUMIRA 825 1,172 1,997
Pediatric Nutritionals 299 480 779
Adult Nutritionals 352 355 707
Coronary Stents 244 281 525
TRILIPIX/TriCor (fenofibrate) 328 91 419
Kaletra 80 256 336
Niaspan 247 -- 247
Lupron 135 70 205
Synthroid 140 29 169
% Change vs. 2Q10
Int'l Total
U.S. Operational Reported Operational Reported
HUMIRA 18.5 18.9 30.6 18.7 25.3
Pediatric
Nutritionals (10.5) 7.7 11.9 (0.3) 2.1
Adult
Nutritionals 5.2 9.1 16.4 7.0 10.5
Coronary Stents (12.9) 1.5 10.9 (6.1) (1.6)
TRILIPIX/TriCor
(fenofibrate) 3.4 6.2 17.9 3.9 6.2
Kaletra (14.0) 19.2 27.4 8.7 14.3
Niaspan 17.2 n/a n/a 17.2 17.2
Lupron 12.0 (3.6) 4.7 6.5 9.4
Synthroid 35.9 5.7 12.4 30.0 31.3
The following is a summary of first-half 2011 sales for select
products.
Sales ($ in millions)
U.S. Int'l Total
HUMIRA 1,455 2,188 3,643
Pediatric Nutritionals 608 926 1,534
Adult Nutritionals 675 695 1,370
Coronary Stents 478 571 1,049
TRILIPIX/TriCor (fenofibrate) 617 173 790
Kaletra 144 441 585
Niaspan 473 -- 473
Lupron 254 135 389
Synthroid 257 57 314
% Change vs. 1H10
Int'l Total
U.S. Operational Reported Operational Reported
HUMIRA 17.5 18.7 24.9 18.2 21.8
Pediatric
Nutritionals (5.5) 8.8 12.9 2.5 4.8
Adult
Nutritionals 3.6 11.7 17.3 7.4 10.1
Coronary Stents (11.4) 19.7 27.4 2.7 6.2
TRILIPIX/TriCor
(fenofibrate) 3.6 75.1 84.4 13.3 14.6
Kaletra (12.4) 0.5 4.5 (3.2) (0.3)
Niaspan 13.9 n/a n/a 13.9 13.9
Lupron 11.4 (2.8) 2.8 6.3 8.3
Synthroid 27.7 5.4 12.0 23.2 24.5
Notes: 1) See "Consolidated Statement of Earnings" for more information.
2) "Operational" growth reflects percentage change over the prior
year excluding the impact of exchange rates.
n/a = Not applicable
Business Highlights
- Initiated Phase 3 Study of Bardoxolone Methyl; Announced
52-week Phase 2 Data: Announced with Reata the beginning
of a pivotal Phase 3 clinical trial to evaluate the safety and
efficacy of bardoxolone methyl in patients with chronic kidney
disease (CKD) and Type 2 diabetes. Results are expected in 2013.
The New England Journal of Medicine published Phase 2 clinical
trial data, showing that bardoxolone has the potential to delay
kidney disease progression. - Launched XIENCE nano to Treat Coronary Artery Disease
in Small Vessels: Launched XIENCE nano™ Everolimus
Eluting Coronary Stent System for the treatment of coronary artery
disease in small vessels in the United States. XIENCE nano offers a
new option for treating patients with coronary artery disease in
vessels as small as 2.25 mm in diameter. - Reported Interim Results from a Phase 3 Study for Advanced
Parkinson’s Disease: Announced interim efficacy and
safety results from a 54-week, Phase 3 open-label study of Abbott’s
investigational treatment for advanced Parkinson’s disease showing
patients treated with levodopa-carbidopa intestinal gel (LCIG) for
12 weeks reported improvement in motor symptoms. LCIG is in Phase 3
development in the United States and is approved for use in 38
countries. - Launched New ZonePerfect Flavors: Introduced new
ZonePerfect® Sweet & Salty nutrition bars, which combine sweet
and salty flavors, while providing excellent nutrition. ZonePerfect
Sweet & Salty bars have 10 grams of protein and 19 vitamins and
minerals providing a convenient, nutritious snack. - Received U.S. Approval for AndroGel 1.62% to Treat Men with
Low Testosterone: Announced U.S. Food and Drug
Administration (FDA) approval of AndroGel® (testosterone gel)
1.62%, a clear, odorless, gel formulation shown to restore
testosterone levels in hypogonadal men with half the volume of gel
at the starting dose compared to AndroGel 1%. - Received FDA Approval for a New Six-Month Formulation of
Lupron Depot: Launched in the United States a new
six-month administration formulation of Lupron Depot® (leuprolide
acetate for depot suspension), a palliative treatment for advanced
prostate cancer. - Submitted New Molecular Test for Non-Small Cell Lung Cancer
Therapy Selection: Submitted regulatory applications in
the United States and Japan for a new molecular diagnostic test
designed to detect abnormal gene rearrangements in non-small-cell
lung cancer tumors. The test is intended to be used with Pfizer’s
crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK)
inhibitor, also under regulatory review. - Announced Agreement with Biotest to Develop Antibody for
Autoimmune Diseases: Announced a global agreement with
Biotest AG to develop and commercialize BT-061, a novel anti-CD4
biologic for the treatment of autoimmune diseases. BT-061 is in
Phase 2 clinical trials for rheumatoid arthritis (RA) and psoriasis
and in preclinical studies in other immune-related diseases. - Received CE Mark for FreeStyle InsuLinx Blood Glucose
Monitoring System: Announced CE Mark for FreeStyle
InsuLinx Blood Glucose Monitoring System, the first blood glucose
monitoring device from Abbott that includes a mealtime (bolus)
insulin calculator. - Received FDA approval for expanded indication for RX
ACCULINK Carotid Stent System: The FDA approved an
expanded indication for RX ACCULINK® to treat patients with carotid
artery disease at standard risk of adverse events from carotid
endarterectomy (surgery).
Abbott raises ongoing EPS guidance; confirms strong
growth outlook for 2011
Abbott is raising its previous ongoing earnings-per-share
guidance range for the full-year 2011, based on strong performance
to date and the outlook for the remainder of the year. As a result,
the new guidance range for full-year 2011 ongoing earnings per
share is $4.58 to $4.68, confirming Abbott’s outlook for
double-digit growth at the midpoint of the range. The previously
issued guidance range was $4.54 to $4.64.
Abbott forecasts specified items for the full-year 2011 of
approximately $0.60 per share, primarily associated with
acquisition integration/cost reduction initiatives, in-process
R&D, partially offset by the favorable impact of the resolution
of various international and U.S. tax positions. Including these
specified items, projected earnings per share under Generally
Accepted Accounting Principles (GAAP) would be $3.98 to $4.08 for
the full-year 2011.
Abbott declares 350th quarterly
dividend
On June 10, 2011, the board of directors of Abbott declared the
company’s quarterly common dividend of 48 cents per share. The cash
dividend is payable Aug. 15, 2011, to shareholders of record at the
close of business on July 15, 2011. This marks the 350th
consecutive dividend paid by Abbott since 1924.
About Abbott
Abbott is a global, broad-based health care company devoted to
the discovery, development, manufacture and marketing of
pharmaceuticals and medical products, including nutritionals,
devices and diagnostics. The company employs nearly 90,000 people
and markets its products in more than 130 countries.
Abbott’s news releases and other information are available on
the company’s Web site at www.abbott.com. Abbott will
webcast its live second-quarter earnings conference call through
its Investor Relations Web site at www.abbottinvestor.com at
8 a.m. Central time today. An archived edition of the call will be
available after 11 a.m. Central time.
-Private Securities Litigation Reform Act of 1995
-
A Caution Concerning Forward-Looking
Statements
Some statements in this news release may be
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995. Abbott cautions that these
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from
those indicated in the forward-looking statements. Economic,
competitive, governmental, technological and other factors that may
affect Abbott’s operations are discussed in Item 1A, “Risk
Factors,” to our Annual Report on Securities and Exchange
Commission Form 10-K for the year ended Dec. 31, 2010, and
are incorporated by reference. Abbott undertakes no obligation to
release publicly any revisions to forward-looking statements as a
result of subsequent events or developments.
Abbott Laboratories and Subsidiaries
Consolidated Statement of Earnings
Second Quarter Ended June 30, 2011 and 2010
(in millions, except per share data)
(unaudited)
2011 2010 % Change
Net Sales $ 9,616 $ 8,826 9.0
Cost of products sold 3,870 3,544 9.2 1)
Research and development 1,038 858 21.0
Acquired in-process research and
development 173 75 n/m
Selling, general and administrative 2,762 2,743 0.7
Total Operating Cost and Expenses 7,843 7,220 8.6
Operating earnings 1,773 1,606 10.4
Net interest expense 115 96 19.7
Net foreign exchange (gain) loss (11) (41) n/m
Other (income) expense, net (6) (8) n/m
Earnings before taxes 1,675 1,559 7.4
Taxes on earnings (268) 267 n/m 2)
Net Earnings $ 1,943 $ 1,292 50.4
Net Earnings Excluding Specified Items,
as described below $ 1,768 $ 1,578 12.1 3)
Diluted Earnings per Common Share $ 1.23 $ 0.83 48.2
Diluted Earnings Per Common Share,
Excluding Specified Items,
as described below $ 1.12 $ 1.01 10.9 3)
Average Number of Common Shares
Outstanding Plus Dilutive
Common Stock Options and Awards 1,566 1,552
1) 2011 Cost of products sold includes approximately $430
million of non-cash intangible amortization.
2) 2011 Taxes on earnings includes a favorable adjustment to tax
expense of $519 million, or $0.33 per share, as a result of
the resolution of various prior years' international and U.S.
tax positions. This favorable item is classified as a
specified item and excluded from ongoing results, as
discussed below.
3) 2011 Net Earnings Excluding Specified Items excludes
after-tax charges of $60 million, or $0.04 per share,
associated with the acquisition of Solvay Pharmaceuticals,
$35 million, or $0.02 per share, for previously announced
cost reduction initiatives and other, $76 million, or $0.05
per share, for the impairment of an R&D intangible asset,
$173 million, or $0.11 per share, relating to acquired
in-process research and development related to the Reata and
Biotest collaborations. These items were offset by a
favorable adjustment from the resolution of prior years'
international and U.S. tax positions for $519 million, or
$0.33 per share.
2010 Net Earnings Excluding Specified Items excludes
after-tax charges of $75 million, or $0.05 per share, for
acquired in-process research and development related to the
Neurocrine collaboration, $106 million, or $0.07 per share,
for a litigation reserve, $83 million, or $0.05 per share,
for closing and integration costs associated with the
acquisition of Solvay Pharmaceuticals and other acquisitions
and $22 million, or $0.01 per share, for cost reduction
initiatives and other.
NOTE: See attached questions and answers section for further explanation
of Consolidated Statement of Earnings line items.
n/m = Percent change is not meaningful.
Abbott Laboratories and Subsidiaries
Consolidated Statement of Earnings
First Half Ended June 30, 2011 and 2010
(in millions, except per share data)
(unaudited)
2011 2010 % Change
Net Sales $ 18,657 $ 16,524 12.9
Cost of products sold 7,729 6,879 12.4 1)
Research and development 1,968 1,588 23.9
Acquired in-process research and
development 273 75 n/m
Selling, general and administrative 5,613 4,906 14.4
Total Operating Cost and Expenses 15,583 13,448 15.9
Operating earnings 3,074 3,076 (0.1)
Net interest expense 239 185 29.3
Net foreign exchange (gain) loss (43) 29 n/m
Other (income) expense, net 135 (19) n/m 2)
Earnings before taxes 2,743 2,881 (4.8)
Taxes on earnings (63) 586 n/m 3)
Net Earnings $ 2,806 $ 2,295 22.3
Net Earnings Excluding Specified
Items, as described below $ 3,186 $ 2,845 12.0 4)
Diluted Earnings per Common Share $ 1.79 $ 1.47 21.8
Diluted Earnings Per Common Share,
Excluding Specified Items,
as described below $ 2.03 $ 1.82 11.5 4)
Average Number of Common Shares
Outstanding Plus Dilutive
Common Stock Options and Awards 1,562 1,557
1) 2011 Cost of products sold includes approximately $830
million of non-cash intangible amortization.
2) Other (income) expense, net for 2011 includes a charge of
$137 million for the impact of Abbott's change to a calendar
year end for the international operations that were
previously reported on a November 30 year-end. This is being
treated as a specified item as noted below.
3) 2011 Taxes on earnings includes a favorable adjustment to tax
expense of $519 million, or $0.33 per share, as a result of
the resolution of various prior years' international and U.S.
tax positions. This favorable item is classified as a
specified item and excluded from ongoing results, as
discussed below.
4) 2011 Net Earnings Excluding Specified Items excludes
after-tax charges of $142 million, or $0.09 per share,
associated with the acquisition of Solvay Pharmaceuticals,
$107 million, or $0.07 per share, for previously announced
restructuring in the pharmaceutical business, $88 million, or
$0.05 per share, for previously announced cost reduction
initiatives and other, $137 million, or $0.09 per share, for
the 2009 and 2010 impact of the change to a calendar year end
for international operations, $273 million, or $0.17 per
share, relating to acquired in-process research and
development related to the Reata and Biotest collaborations,
$76 million, or $0.05 per share, for the impairment of an R&D
intangible asset, and $76 million, or $0.05 per share, for
litigation reserves. These items were offset by a favorable
adjustment from the resolution of prior years' international
and U.S. tax positions for $519 million, or $0.33 per share.
2010 Net Earnings Excluding Specified Items excludes
after-tax charges of $115 million, or $0.07 per share, for
the one-time impact of the devaluation of the Venezuelan
bolivar on balance sheet translation, $75 million, or $0.05
per share, relating to acquired in-process research and
development related to the Neurocrine collaboration, $106
million, or $0.07 per share, for a litigation reserve, $136
million, or $0.09 per share, for closing and integration
costs associated with the acquisition of Solvay
Pharmaceuticals and other acquisitions, $60 million, or $0.04
per share, for specific health care reform impact on deferred
tax assets, and $58 million, or $0.03 per share, for cost
reduction initiatives and other.
NOTE: See attached questions and answers section for further explanation
of Consolidated Statement of Earnings line items.
n/m = Percent change is not meaningful.
Questions & Answers
Q1) What drove the strong sales growth?
A1) Beginning this year, we have characterized Abbott’s
major businesses into three categories, based on their underlying
attributes. These include:
- Proprietary Pharmaceuticals, including our U.S. and
international proprietary pharmaceutical products. We recently
globalized this business, creating one division to allow for
streamlined commercial efforts and coordination between functions.
- Durable Growth Businesses, including Nutritionals,
Established Pharmaceuticals, Core Laboratory Diagnostics, Diabetes
Care and Point of Care Diagnostics. These businesses are less
dependent on significant R&D investment, have minimal patent
risk, and operate in generally stable markets, with many products
paid for directly by the consumer. - Innovation-Driven Device Businesses, including Vascular,
Medical Optics and Molecular Diagnostics. These businesses have a
relatively lower patent risk, and require a moderate level of
R&D spend, resulting in new products that generate more
significant revenue and profit contribution.
Proprietary Pharmaceuticals sales increased 13 percent,
including 4.1 percent from favorable foreign exchange, driven by
strong growth across a number of key franchises in the United
States and internationally. HUMIRA® was a significant contributor
to growth in the quarter with U.S. sales growth of 18.5 percent and
International sales growth of 30.6 percent.
Durable Growth Businesses sales increased 7.5 percent, including
5.1 percent favorable foreign exchange, driven by Established
Pharmaceuticals and steady sales growth in Core Laboratory
Diagnostics, Diabetes Care and Point of Care Diagnostics
businesses. Established Pharmaceuticals sales, which include sales
of our branded generics pharmaceuticals outside of the United
States, increased 10.3 percent, including the contribution from the
Piramal Healthcare Solutions acquisition. Worldwide Nutritional
products sales growth was 5.4 percent, with 13.7 percent growth in
International Nutritionals. Nutritional sales in the United States
during the quarter were negatively impacted by the infant nutrition
recall that was announced in September 2010, as previously
forecasted.
Innovation-Driven Device Business sales increased 3.1 percent,
including 5 percent favorable foreign exchange, driven by
double-digit growth in Molecular Diagnostics, 10.4 percent growth
in International Vascular and 7.5 percent growth in Medical
Optics.
Q2) What were emerging markets
sales?
A2) Emerging market sales within each division were as
follows (dollars in millions):
2Q11 Emerging
Markets Sales*
Reported %
Sales Growth
Established Pharmaceuticals $776 24.6
Nutritionals $629 15.6
Proprietary Pharmaceuticals $595 40.8
Core Laboratory Diagnostics $301 9.3
Vascular $145 25.4
Other $147 18.5
Total $2,593 23.2
* Emerging markets sales include revenues from all countries and regions
excluding the developed world: United States, Canada, Western Europe,
Japan and Australia.
Abbott total company emerging markets sales grew 23.2 percent in
the quarter, reflecting strong growth across all divisions,
underscoring the importance of these markets to Abbott’s growth
profile. In our Established Pharmaceuticals business, we saw strong
performance in Russia, India and China. In Nutritionals, we saw
particularly strong growth in Asia and Latin America, where we are
expanding our presence and gaining share with the introduction of
new products.
In our Diagnostics business, we continue to perform well in
China, where we are placing new ARCHITECT® systems and continuing
to penetrate the market. And, in our Vascular business, we saw
strong growth across all key emerging markets, driven by
double-digit procedure volumes in many of these markets, as well as
Abbott market share gains.
Q3) What was the gross margin ratio in the
quarter?
A3) The gross margin ratio before and after specified
items is shown below (dollars in millions):
2Q11
Cost of Gross
Products Gross Margin
Sold Margin %
As reported (GAAP) $3,870 $5,746 59.8%
Adjusted for specified item:
Restructuring/integration (acquisitions/cost
reductions) ($43) $43 0.4%
As adjusted $3,827 $5,789 60.2%
The adjusted gross margin ratio of 60.2 percent in the second
quarter was above our previous outlook for the quarter, driven by
favorable product mix.
Q4) What drove SG&A and
R&D investment?
A4) Both SG&A and R&D investment reflects Abbott’s
continued investment in programs to drive future growth. R&D
expense reflects continued investment in Abbott’s broad-based
pipeline, including programs in vascular devices, immunology,
neuroscience, oncology and HCV.
Q5) What was the tax rate?
A5) The ongoing tax rate this quarter was 15.2 percent, in
line with Abbott’s previous forecast, and reconciled below (dollars
in millions):
2Q11
Pre-Tax Taxes on Tax
Income Earnings Rate
As reported $1,675 ($268) n/m
Specified items $410 ($585) n/m
Excluding specified items $2,085 $317 15.2%
n/m = Percent change is not meaningful.
Reported taxes on earnings in the quarter includes a favorable
adjustment to tax expense of $519 million, or $0.33 per share, as a
result of the resolution of various prior years’ international and
U.S. tax positions. This favorable item is classified as a
specified item and excluded from ongoing results.
Q6) How did specified items affect reported
results?
A6) Specified items impacted second-quarter results as
follows:
2Q11
(dollars in millions, except earnings-per-share) Earnings
Pre- After-
tax tax EPS
As reported (GAAP) $1,675 $1,943 $1.23
Adjusted for specified items:
Restructuring/integration (acquisitions/cost
reductions) $112 $95 $0.06
Resolution of tax positions --- ($519)($0.33)
Acquired in-process research and development $173 $173 $0.11
Intangible asset impairment $125 $76 $0.05
As adjusted $2,085 $1,768 $1.12
Restructuring/integration (acquisitions/cost reductions) is
primarily associated with restructuring and integration costs for
the Solvay Pharmaceuticals acquisition. This item also includes
previously announced cost reduction initiatives to improve
efficiencies in the vascular and core laboratory diagnostic
businesses. Acquired in-process research and development is related
to an agreement with Biotest on the development of BT-061 for RA,
psoriasis and other immune-related diseases, as well as an
agreement with Reata to develop and commercialize bardoxolone
methyl outside the U.S., excluding certain Asian markets.
Intangible asset impairment is related to the write down of an
acquired research and development intangible asset in a non-segment
business.
2011 Taxes on earnings includes a favorable adjustment to tax
expense of $519 million, or $0.33 per share, as a result of the
resolution of various prior years’ international and U.S. tax
positions. The impact of the remaining specified items by
Consolidated Statement of Earnings line item is as follows (dollars
in millions):
2Q11
Cost of Other
Products Acquired (Income)/
Sold R&D IPR&D SG&A Expense
As reported (GAAP) $3,870 $1,038 $173 $2,762 ($6)
Adjusted for specified
items:
Restructuring/integration
(acquisitions/cost
reductions) ($43) ($17) -- ($49) ($3)
Acquired in-process
research and development -- -- ($173) -- --
Intangible asset
impairment -- ($125) -- -- --
As adjusted $3,827 $896 -- $2,713 ($9)
Q7) What are the key areas of focus in Abbott’s
broad-based pipeline?
A7) We continue to advance our broad-based pipeline. In
the first half of 2011, we launched several new products or
indications, including Lupron 6-Month Depot, Androgel 1.62%, the
Creon infant-specific dosage, XIENCE nano, TREK® Coronary Balloon
System and the FreeStyle InsuLinx Blood Glucose Monitoring System.
We advanced elotuzumab and bardoxolone into Phase 3 development and
submitted XIENCE PRIME™, HUMIRA ulcerative colitis (UC) and our ALK
gene molecular diagnostics test for regulatory review. Following
are highlights from breakthrough research across our
pharmaceuticals, medical products and nutritionals pipelines:
- Hepatitis C
- Abbott’s antiviral program is focused on developing treatments
for hepatitis C (HCV), a disease that affects more than 180 million
people worldwide, with approximately 3 to 4 million people newly
infected each year. Abbott’s broad-based HCV programs include its
partnership with Enanta Pharmaceuticals to discover protease
inhibitors, as well as its internal programs focused on additional
viral targets. - Abbott currently has three mechanisms of action in Phase 2
clinical trials, including protease, polymerase and NS5A
inhibitors. Abbott is well positioned to explore combinations of
these compounds, both with and without the current standard of
care, a strategy that has the potential to markedly transform
current treatment practices by shortening therapy duration,
improving tolerability and increasing cure rates.
- Abbott’s antiviral program is focused on developing treatments
- Chronic Kidney Disease
- Bardoxolone, an investigational treatment for chronic kidney
disease (CKD), is a first-in-class anti-inflammatory that activates
Nrf2, a pathway involved in the progression of CKD. A Phase
2b study was recently completed, and a global Phase 3 trial was
recently initiated. Abbott’s agreement with Reata Pharmaceuticals
includes international rights to bardoxolone, excluding certain
Asian markets.
- Bardoxolone, an investigational treatment for chronic kidney
- Women’s Health
- Elagolix, a novel, first-in-class oral gonadotropin-releasing
hormone (GnRH) is in development for the treatment of
endometriosis-related pain and fibroids. A Phase 2 study in
endometriosis was recently completed. Abbott is working in
partnership with Neurocrine to finalize the Phase 3 program in
endometriosis and a Phase 2 study in uterine fibroids.
- Elagolix, a novel, first-in-class oral gonadotropin-releasing
- Neuroscience / Pain
- Abbott is conducting innovative research in neuroscience, where
it has developed compounds that target receptors in the brain that
help regulate mood, memory and other neurological functions. Abbott
has more than a dozen new molecular entities in clinical trials for
conditions such as schizophrenia, pain, Alzheimer’s disease,
Parkinson’s disease and multiple sclerosis (MS). - Abbott’s neuroscience pipeline includes a novel,
next-generation antibody, daclizumab, which entered Phase 3
development in 2010 for MS. We expect to present data from the
Phase 2 SELECT trial later this year. - Abbott is pursuing compounds that could provide relief across a
broad spectrum of pain states, such as chronic back pain,
postoperative pain and cancer pain.
- Abbott is conducting innovative research in neuroscience, where
- Oncology
- Abbott’s oncology pipeline includes therapies that represent
promising, unique scientific approaches to treating cancer. Abbott
is focused on the development of targeted treatments that inhibit
tumor growth and improve response to common cancer therapies.
Abbott currently has 11 new molecular entities in human trials for
cancer. - The oncology pipeline includes: ABT-869, a multi-targeted
kinase inhibitor; ABT-263, a Bcl-2 family protein antagonist; and
ABT-888, a PARP-inhibitor. Each is being studied in a variety of
cancers. Additionally, Abbott is evaluating a number of other
promising mechanisms, including work on EFGR, CD37, aurora kinase
and cMET, among others. - The acquisition of Facet Biotech brought several oncology
collaborations, including elotuzumab, currently in Phase 3
development for multiple myeloma.
- Abbott’s oncology pipeline includes therapies that represent
- Immunology
- Abbott’s scientific experience with the anti-TNF biologic
HUMIRA serves as a strong foundation for its continuing research in
immunology. Abbott is developing a number of additional indications
for HUMIRA and is working to advance its early discovery programs,
including oral DMARD therapies, and other potential biologic
targets. We recently submitted U.S. and European regulatory
applications for HUMIRA as a treatment for UC. - Our agreement with Biotest brings Abbott rights to develop and
commercialize BT-061, a novel anti-CD4 biologic in Phase 2
development for rheumatoid arthritis and psoriasis. - Additionally, Abbott’s proprietary DVD-Ig technology represents
an innovative approach that can target multiple disease-causing
antigens with a single biologic agent. This technology could lead
to combination biologics for complex conditions such as cancer or
rheumatoid arthritis, where multiple pathways are involved in the
disease. We expect this program to move into Phase I clinical
trials by year end.
- Abbott’s scientific experience with the anti-TNF biologic
- Molecular Diagnostics
- Abbott expects to launch more than 12 new molecular diagnostic
products over the next few years, including several novel oncology
and infectious disease assays. In 2011, Abbott received FDA
approval for the Abbott RealTime PCR HCV assay for measuring
viral load or the amount of hepatitis C virus in a patient’s blood,
as well as CE Mark for a new test to detect cytomegalovirus (CMV),
a virus that can lead to complications in transplant patients and
people who are immunocompromised. Abbott has submitted an ALK gene
rearrangement test for non-small cell lung cancer to be used in
combination with Pfizer’s crizotinib, an oral first-in-class
anaplastic lymphoma kinase (ALK) inhibitor.
- Abbott expects to launch more than 12 new molecular diagnostic
- Diagnostics
- Abbott has launched a number of key assays on its ARCHITECT
immunochemistry platform, which will significantly broaden its
industry-leading menu. These tests include assays to assess Chagas
disease, ovarian cancer and the first HIV combination assay
approved for use in the United States. Abbott expects to launch
several more products this year and is researching novel biomarkers
focusing on important areas such as infectious disease and other
critical therapeutic areas, as well as developing next-generation
systems.
- Abbott has launched a number of key assays on its ARCHITECT
- Vascular Devices
- Abbott has one of the industry’s most robust vascular pipelines
and expects to deliver approximately 10 new technologies over the
next five years. Abbott is working on well-staged incremental
advances, and truly game-changing technologies that have the
ability to restate the market. - ABSORB Bioresorbable Vascular Scaffold (BVS) - Abbott
received CE Mark in Europe for the world’s first drug-eluting BVS
for the treatment of coronary artery disease. ABSORB™ restores
blood flow by opening a clogged vessel and providing support to the
vessel until it dissolves, leaving patients with a treated vessel
free of a permanent metallic implant. Abbott has the most advanced
BVS clinical program in the industry. - MitraClip - MitraClip® is a minimally invasive
device for the treatment of select patients with mitral
regurgitation (MR), the most common valve disease in the world.
Significant MR affects more than 8 million people in the United
States and Europe, and is four times more prevalent than aortic
stenosis. Abbott’s MitraClip system is on the market outside the
United States and is currently under FDA review. - Next-generation DES - Abbott has several
next-generation DES platforms in development. Our XIENCE nano DES
for small vessels, which is on the market in Europe, recently
launched in the United States. XIENCE PRIME, our next-generation
drug-eluting stent (DES), offers improved deliverability,
especially in long lesions. XIENCE PRIME is on the market in Europe
with an expected U.S. launch in 2012. Our ultra thin DES is also in
development. It’s designed to improve clinical outcomes by reducing
vessel injury upon deployment, enabling faster healing and
improving deliverability in complex anatomy. - Core Coronary products - Abbott is continuing to expand
its position in the more than $2 billion core coronary market.
Abbott launched its next-generation balloon dilatation catheter,
TREK, in Europe last year and in the United States and Japan in
early 2011, and plans to introduce additional balloon products and
next-generation guide wires within the next few years. - Endovascular products - Abbott’s endovascular business
continues to grow, led by recent launches of key products,
including the Armada 14 balloon line, the expanded indication for
the RX ACCULINK Carotid Stent System and R&D investments into
growth segments of the market for peripheral artery disease and
vessel closure.
- Abbott has one of the industry’s most robust vascular pipelines
- Vision Care
- Abbott expects 20 new products and technology advancements over
the next five years, including the launch of a new contact lens
solution that is underway in Europe and the United States. In its
market-leading LASIK business, Abbott is expanding its proprietary
laser platform into new vision correction applications, including
cataract surgery. Abbott also continues to expand its premium and
standard intraocular lenses (IOL), including Synchrony®, its
next-generation IOL approved in Europe and other countries around
the world. Synchrony is currently under FDA review in the United
States.
- Abbott expects 20 new products and technology advancements over
- Nutrition
- Abbott is focused on improving six areas through nutrition:
immunity, cognition, lean body mass, inflammation, metabolism and
tolerance. We expect to launch a number of new products and
formulations to consumers in 2011 and are currently conducting 30
well-controlled clinical trials to demonstrate proven clinical
outcomes with our nutrition innovation. Abbott has introduced
several new products, including Ensure® with Revigor™, PediaSure
SideKicks™ and ZonePerfect Sweet & Salty nutrition bars.
- Abbott is focused on improving six areas through nutrition:
Financial, John Thomas, +1-847-938-2655, or Larry Peepo, +1-847-935-6722, or Tina Ventura, +1-847-935-9390, or Media, Melissa Brotz, +1-847-935-3456, or Scott Stoffel, +1-847-936-9502, or Adelle Infante, +1-847-938-8745
Tags: Abbott, Abbott park, Illinois, July 20
